The opportunity
Anthropic is seeking an experienced Corporate Development leader to drive our strategic transactions in life sciences and biotech. Frontier AI is beginning to change how drugs are discovered, developed, and brought to patients, and Anthropic wants to help build that future responsibly.
What you'll do
Define and execute Anthropic's corporate development strategy in life: sciences, covering acquihires, tuck-in acquisitions, minority investments, and strategic partnerships
Build and maintain a target pipeline across AI-native companies in drug: discovery, clinical development, regulatory and medical writing, lab automation, and healthcare data infrastructure
Lead end-to-end transaction processes, from sourcing through diligence, negotiation, signing, and integration
Partner with research, product, engineering, and go-to-market teams to assess: the technical, scientific, and commercial value of opportunities
Run sector-specific diligence, including scientific and data validation,: regulatory posture (FDA, EMA, GxP, 21 CFR Part 11), data privacy (HIPAA, GDPR), quality systems, and IP
Assess build/partner/buy tradeoffs and competitive dynamics against: incumbents, AI-native entrants, and other frontier AI labs
What they're looking for
- Have 8-12 years of experience across corporate development, investment: banking, or investing, with at least 5 years focused on life sciences, biotech, or healthcare technology
- Hold an advanced degree in the life sciences (PhD, MD, PharmD) or an MBA
- Have worked at a pharmaceutical company, biotech, CRO, or life sciences software company
- Have experience with AI/ML applied to biology, chemistry, or clinical operations
- Bring an established network among life sciences founders, healthcare VCs,: and pharma business development leaders
- Have diligenced or integrated businesses operating under GxP, HIPAA, or similar regulatory regimes
- Have led post-merger integration or built a new business unit
- Have experience with cross-border transactions, particularly in the US, EU, and UK life sciences markets
